EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 7, 2005--Dutton Associates continues coverage of Neoprobe Corporation (OTCBB:NEOP), raising its rating to Strong Speculative Buy and setting a...
Dutton Associates Announces Investment Opinion: Neoprobe Lowered to Neutral Rating by Dutton Associates
EL DORADO HILLS, Calif.
Dutton Associates
John M. Dutton, 916-941-8119
Dutton...
Neoprobe to Present at Rodman & Renshaw Techvest; Provides Business Update
DUBLIN, Ohio
Neoprobe Corporation
Brent Larson, 614-793-7500
or
The Trout Group
Tim Ryan, 212-477-9007
Neoprobe...
#13: NEOP Neoprobe Announces First Quarter Results; First Quarter Device Sales Increase 20% Over Prior Year; Business Update Provided and Conference Call Scheduled
Neoprobe Expands Lymphoseek Field of Use; Option Agreement Extends to Optical and Ultrasound Applications
DUBLIN, Ohio
Neoprobe Corporation
Brent Larson, 614-793-7500
OR
The Trout Group
...
Neoprobe Licenses RIGS-Related Patents; Patents Extend Methodology Protection Through 2018
DUBLIN, Ohio
Neoprobe Corporation
Brent Larson, 614-793-7500
or
The Trout Group
Tim Ryan,...
#8: NEOP Neoprobe Files Amendment to Corporate IND for Lymphoseek; Amendment Submission Includes Protocol and Investigators Brochure for Multi-center Study
Neoprobe Files Amendment to Corporate IND for Lymphoseek; Amendment Submission Includes Protocol and Investigators Brochure for Multi-center Study
DUBLIN, Ohio
Neoprobe Corporation
Brent...
Neoprobe to Present at Convergence: the Device/Drug Summit March 23, 2005
DUBLIN, Ohio--(BUSINESS WIRE)--March 22, 2005--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative...